Haemonetics Stock Today
| HAE Stock | USD 85.55 0.12 0.14% |
Performance7 of 100
| Odds Of DistressLess than 6
|
Haemonetics is trading at 85.55 as of the 24th of November 2024, a 0.14% increase since the beginning of the trading day. The stock's lowest day price was 84.5. Haemonetics has only a 6 % chance of going through financial distress over the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Haemonetics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of September 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 9th of May 1991 | Category Healthcare | Classification Health Care |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. The company has 50.22 M outstanding shares of which 5.16 M shares are currently shorted by investors with about 10.59 days to cover. More on Haemonetics
Moving together with Haemonetics Stock
Moving against Haemonetics Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Haemonetics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Christopher Simon | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [HAEMATO, HAEMATO, HAEMATO AG, HAEMATO AG] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NYSE Composite, SP Midcap 400, Medical Equipment, Baby Boomer Prospects, Obamacare Repeal, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHaemonetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Haemonetics' financial leverage. It provides some insight into what part of Haemonetics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Haemonetics (HAE) is traded on New York Stock Exchange in USA. It is located in 125 Summer Street, Boston, MA, United States, 02110 and employs 3,657 people. Haemonetics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 4.3 B. Haemonetics runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 50.22 M outstanding shares of which 5.16 M shares are currently shorted by investors with about 10.59 days to cover.
Haemonetics has about 284.47 M in cash with 181.75 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.79.
Check Haemonetics Probability Of Bankruptcy
Ownership AllocationThe majority of Haemonetics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Haemonetics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Haemonetics. Please pay attention to any change in the institutional holdings of Haemonetics as this could imply that something significant has changed or is about to change at the company.
Check Haemonetics Ownership Details
Haemonetics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Schroder Investment Management Group | 2024-06-30 | 925.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 834 K | |
| Westfield Capital Management Company, Lp | 2024-09-30 | 823.7 K | |
| Btim Corp | 2024-09-30 | 809.6 K | |
| Royal Bank Of Canada | 2024-06-30 | 791.7 K | |
| Fmr Inc | 2024-09-30 | 774.5 K | |
| Fisher Asset Management, Llc | 2024-09-30 | 689.5 K | |
| Franklin Resources Inc | 2024-09-30 | 682 K | |
| Sg Capital Management, Llc | 2024-09-30 | 643.4 K | |
| Blackrock Inc | 2024-06-30 | 6 M | |
| Vanguard Group Inc | 2024-09-30 | 5.2 M |
Haemonetics Historical Income Statement
Haemonetics Stock Against Markets
Haemonetics Corporate Directors
| Robert Abernathy | Independent Director | Profile | |
| Claire Pomeroy | Independent Director | Profile | |
| Catherine Burzik | Independent Director | Profile | |
| Mark Kroll | Independent Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share 26.77 | Quarterly Revenue Growth 0.086 | Return On Assets 0.0588 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.